← Back to Search

Alkylating agents

HIPEC for Adrenocortical Cancer

Phase 2
Recruiting
Led By Michael Kluger, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Hematology: Absolute neutrophil count greater than 1500/mm^3 without the support of Filgrastim
Clinical performance status of Eastern Cooperative Oncology Group (ECOG) less than or equal to 2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is looking at the effectiveness of surgery and chemotherapy in treating patients with adrenocortical cancer that has spread to the abdomen.

Who is the study for?
This trial is for adults with Adrenocortical Carcinoma (ACC) where the majority of cancer is in the peritoneal cavity and can be surgically removed or treated with radiofrequency ablation. Participants must have a life expectancy over three months, practice birth control, and have adequate organ function. Excluded are those with severe heart, lung conditions, active infections, significant neuropathy, brain metastases or pregnant/breastfeeding women.Check my eligibility
What is being tested?
The study tests if surgery followed by Heated Intraperitoneal Chemotherapy (HIPEC) using cisplatin improves survival without cancer spreading inside the abdomen. It also examines side effects, quality of life changes post-treatment and whether cancer comes back locally or spreads elsewhere.See study design
What are the potential side effects?
Potential side effects include complications from major surgery and chemotherapy such as infection risk increase, bleeding issues due to low platelet counts, kidney damage indicated by elevated creatinine levels or reduced clearance rate; liver problems shown by high AST/ALT levels; blood clotting difficulties seen in abnormal prothrombin time.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My white blood cell count is healthy without needing medication.
Select...
I can perform daily activities with minimal assistance.
Select...
My scans show that my cancer can be surgically removed.
Select...
I am 18 years old or older.
Select...
My disease can be seen on a CT or PET scan.
Select...
My cancer is mainly in the belly area and can be surgically removed or treated with a special procedure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival
Secondary outcome measures
Morbidity Rate
Overall Survival
Quality of Life (QOL) Score

Side effects data

From 2012 Phase 3 trial • 256 Patients • NCT01005680
51%
Neutropenia
47%
Leukopenia
46%
Nausea
43%
Vomiting
35%
Anaemia
31%
Decreased appetite
26%
Haemoglobin decreased
26%
Fatigue
25%
Constipation
25%
White blood cell count decreased
24%
Neutrophil count decreased
19%
Alanine aminotransferase increased
13%
Platelet count decreased
12%
Rash
10%
Aspartate aminotransferase increased
10%
Thrombocytopenia
9%
Blood sodium decreased
8%
Hypokalaemia
7%
Insomnia
7%
Pyrexia
6%
Hyponatraemia
6%
Blood creatinine increased
6%
Lymphopenia
6%
Diarrhoea
6%
Dyspepsia
6%
Red blood cell count decreased
6%
Cough
4%
Dizziness
2%
Bone marrow failure
1%
Ischaemic stroke
1%
Cerebral infarction
1%
Dyspnoea
1%
Pulmonary embolism
1%
Embolism venous
1%
Superior vena cava syndrome
100%
80%
60%
40%
20%
0%
Study treatment Arm
Gemcitabine Plus Cisplatin (GC)
Pemetrexed Plus Cisplatin (PC)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Surgery with HIPECExperimental Treatment3 Interventions
Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cytoreductive surgery
2013
Completed Phase 3
~180
Sodium thiosulfate
2009
Completed Phase 2
~50
Cisplatin
2013
Completed Phase 3
~1940

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,433 Previous Clinical Trials
2,450,985 Total Patients Enrolled
Michael Kluger, MD4.930 ReviewsPrincipal Investigator - Columbia University
Columbia University
5Patient Review
Dr. Kluger was excellent. He was very informative and easy to talk to. I feel confident in his abilities and would recommend him to others.

Media Library

Cisplatin (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT03127774 — Phase 2
Adrenocortical Cancer Research Study Groups: Surgery with HIPEC
Adrenocortical Cancer Clinical Trial 2023: Cisplatin Highlights & Side Effects. Trial Name: NCT03127774 — Phase 2
Cisplatin (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03127774 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What conditions does Cisplatin usually help manage?

"Cisplatin is an effective treatment against neoplasm metastasis, advanced ovarian cancer, and advanced testicular cancer."

Answered by AI

Could I possibly join this clinical trial?

"The eligibility requirements for this clinical trial are that patients must have peritoneal carcinomatosis and be aged 18 to 99. A total of 30 people are needed for the study."

Answered by AI

Are there dangerous side effects associated with Cisplatin?

"Cisplatin is a Phase 2 drug, which means that while there are some data supporting its safety, there are no clinical trials demonstrating its efficacy."

Answered by AI

Does this research project test subjects of an older age demographic?

"Eligibility for this clinical trial is restricted to patients aged 18 to 99. There are currently 136 studies underway for patients younger than 18 and 3,245 studies being conducted with seniors aged 65 and up."

Answered by AI

Are there other scientific papers that mention Cisplatin?

"725 clinical trials are currently studying Cisplatin. 286 of those are Phase 3 trials, which tend to have the most promising data. Though many of these studies originate in Shanghai, there are 43323 locations running them globally."

Answered by AI

Are patients currently being accepted into this trial?

"That is correct. The clinical trial, which as of now is looking for 30 participants from 1 site, was updated most recently on March 17th, 2022."

Answered by AI

How many people have agreed to take part in this research project?

"According to the clinicaltrials.gov website, this clinical trial is still recruiting patients. The trial was first posted on September 22nd 2017 and was last updated on March 17th 2022. They are currently looking for 30 patients at 1 location."

Answered by AI
~6 spots leftby Dec 2025